Expression of selected proteins in breast cancer brain metastases

Folia Histochemica et Cytobiologica

Volumn 51, Issue 3, 2013, Pages 213-218

  Gojis, Ondrej ^a   Kubecova, Martina ^a   Rosina, Jozef ^b   Vranova, Jana ^b   Celko, Martin ^b   Frajerova, Denisa ^b   Zmrhal, Jan ^a   Zahumensky, Jozef ^a   Bacova, Tereza ^b   Baca, Vaclav ^b   Mandys, Vaclav ^a   Kucera, Eduard ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Brain metastases; Breast cancer; CK5 6; EGFR; ER; Her2; Immunohistochemistry; Ki67; Pax2; PgR; SRC3

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR PAX2;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIMARY TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR RECEPTOR COACTIVATOR 3; PAX2 TRANSCRIPTION FACTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE;

EID: 84887327848     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2013.0030     Document Type: Article

References (20)

1. Bautista S, Valles H, Walker RL et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res. 1998;4:2925-2929.
2. Wang H, Zhang D, Wu W et al. Overexpression and gender- specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem. 2010;58:1121-1127.
3. Xu J, Liao L, Ning G et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA. 2000;97:6379-6384.
4. Zhou G, Hashimoto Y, Kwak I et al. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol. 2003;23:7742-7755.
5. Yan J, Yu CT, Ozen M et al. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006;66:11039-11046.
6. Anzick SL, Kononen J, Walker RL et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277:965-968.
7. List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2001;68:21-28.
8. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353-361.
9. Muratovska A, Zhou C, He S et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene. 2003;22:7989-7997.
10. Hurtado A, Holmes KA, Geistlinger TR et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature. 2008;456:663-666.
11. O-Charoenrat P, Rhys-Evans P, Modjtahedi H et al. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer. 2000;86:307-317.
12. Jiang J, Sarwar N, Peston D et al. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res. 2007;13:5769-5776.
13. List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2001;68:21-28.
14. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer. 1989;60:252-257.
15. Li BD, Byskosh A, Molteni A et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol. 1994;57:71-77.
16. Shimizu C, Fukutomi T, Tsuda H et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol. 2000;73: 17-20.
17. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103:1763-1769.
18. Gancberg D, Di leo A, Cardoso F et al. Comparison of HER- 2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036-1043.
19. Regitnig P, Schippinger W, Lindbauer M et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol. 2004;203:918-926.
20. Pectasides D, Gaglia A, Arapantoni-Dadioti P et al. HER-2/ /neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res. 2006;26: 647-653.